VIVUS, Inc.  

(Public, NASDAQ:VVUS)   Watch this stock  
Find more results for VVUS
5.36
+0.11 (2.10%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.13 - 5.36
52 week 4.71 - 15.62
Open 5.26
Vol / Avg. 2.25M/3.20M
Mkt cap 552.94M
P/E     -
Div/yield     -
EPS -1.73
Shares 103.16M
Beta 1.32
Inst. own 86%
Jun 20, 2014
Vivus Inc. Annual Shareholder Meeting Add to calendar
May 5, 2014
Q1 2014 Vivus Inc. Earnings Release (Estimated) Add to calendar
Apr 8, 2014
Vivus Inc. at Needham Healthcare Conference
Mar 10, 2014
Vivus Inc. at ROTH Conference
Mar 5, 2014
Vivus Inc. at Cowen Health Care Conference
Feb 24, 2014
Q4 2013 Vivus Inc. Earnings Conference Call - Webcast
Feb 24, 2014
Q4 2013 Vivus Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -38.96% -215.76%
Operating margin -19.74% -190.69%
EBITD margin - -149.17%
Return on average assets -16.12% -50.28%
Return on average equity -44.82% -92.99%
Employees 98 -
CDP Score - -

Address

STE 200, 1172 CASTRO ST
MOUNTAIN VIEW, CA 94040
United States - Map
+1-650-9345265 (Phone)
+1-650-9345389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil.

Officers and directors

Michael James Astrue Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Seth H. Z. Fischer Chief Executive Officer, Chief Commercial Officer, Director
Age: 57
Bio & Compensation  - Reuters
Svai Sanford Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 43
Bio & Compensation  - Reuters
Guy P. Marsh Vice President - U.S. Operations, General Manager
Age: 59
Bio & Compensation  - Reuters
Wesley W. Day Ph.D. Vice President - Clinical Development
Age: 49
Bio & Compensation  - Reuters
John L. Slebir Esq. Vice President - Business Development, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Samuel F. Colin M.D. Director
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Director
Age: 44
Bio & Compensation  - Reuters
Johannes J. P. Kastelein Director
Bio & Compensation  - Reuters
David York Norton Director
Bio & Compensation  - Reuters